BRAF and melanoma: This observation was specific to BRAFV600E CRC, as it was not recapitulated in vemurafenib-sensitive BRAFV600E melanoma cells (A375, A375 (SRCY530F), A375 (myr-AKT1), Sk-Mel-28, Mel888) or BRAF-wild-type CRC cells (HCT116, LoVo), as shown in Fig. 2b and Extended Data Fig. 2a.